NVS vs. RVTY: Novartis vs. Revvity Stock Comparison

Company Profile

Novartis (NVS) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVS is classified in Pharmaceuticals while RVTY is classified in Life Sciences Tools & Services.

Revvity (RVTY) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Novartis (NVS) at 24.33% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for NVS.

For every dollar of sales, both Novartis (NVS) at 17.49% and Revvity (RVTY) at 8.61% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Novartis (NVS) at 34.27% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Novartis (NVS) at 9.57% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Novartis (NVS) at 21.81% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Novartis (NVS) at 0.88 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVS.

Revvity (RVTY) at 0.38 carries an industry-typical debt-to-equity mix, while Novartis (NVS) at 1.29 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Novartis (NVS) at 2.88% and Revvity (RVTY) at 0.19% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Novartis (NVS) at 90.46% and Revvity (RVTY) at 13.40% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Novartis (NVS) at 31.02 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Novartis (NVS) at 5.35 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Revvity (RVTY) at 2.39 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.

Valuation Metrics